Sensitization in Heart Transplantation: Emerging Knowledge

March 19, 2019 e553 Monica M. Colvin, MD, MS, FAHA, Chair Jennifer L. Cook, MD, FAHA, Vice Chair Patricia P. Chang, MD, MHS Daphne T. Hsu, MD, FAHA Michael S. Kiernan, MD, MSc, FAHA Jon A. Kobashigawa, MD, FAHA JoAnn Lindenfeld, MD, FAHA S. Carolina Masri, MD Dylan V. Miller, MD E. Rene Rodriguez, MD Dolly B. Tyan, PhD Adriana Zeevi, PhD On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Cardiovascular Surgery and Anesthesia

[1]  B. Levin,et al.  Ventricular assist device elicits serum natural IgG that correlates with the development of primary graft dysfunction following heart transplantation. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  D. Mancini,et al.  Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  J. Kobashigawa,et al.  Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  A. Zeevi,et al.  Significance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes , 2017, Front. Immunol..

[5]  A. Israni,et al.  OPTN/SRTR 2015 Annual Data Report: Heart , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  G. Berry,et al.  The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody‐Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  Jean Kanitakis,et al.  An integrated view of immune monitoring in vascularized composite allotransplantation , 2016, Current opinion in organ transplantation.

[8]  Gordon D. Wu,et al.  Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization. , 2016, Transplant immunology.

[9]  J. Patel,et al.  Desensitization strategies in adult heart transplantation-Will persistence pay off? , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  P. Rowe,et al.  A reliable method for avoiding false negative results with Luminex single antigen beads; evidence of the prozone effect. , 2016, Transplant immunology.

[11]  G. Ghiggeri,et al.  Acquisition of C3d‐Binding Activity by De Novo Donor‐Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  P. Oyer,et al.  Influence of durable mechanical circulatory support and allosensitization on mortality after heart transplantation. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  A. Ducharme,et al.  Multicenter evaluation of a national organ sharing policy for highly sensitized patients listed for heart transplantation in Canada. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  D. Mancini,et al.  The Impact of Donor Specific Antibodies on Antibody Mediated Rejection , 2016 .

[15]  J. Patel,et al.  Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  L. Rostaing,et al.  Belatacept and Long-Term Outcomes in Kidney Transplantation. , 2016, The New England journal of medicine.

[17]  X. Jouven,et al.  Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody‐Mediated Rejection , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  P S Heeger,et al.  Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation‐05 Study , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  J. Kautzner,et al.  Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance , 2016, Transplant international : official journal of the European Society for Organ Transplantation.

[20]  B. Chung,et al.  Increase of Th17 Cell Phenotype in Kidney Transplant Recipients with Chronic Allograft Dysfunction , 2015, PloS one.

[21]  N. Maillard,et al.  Protein A-Based Immunoadsorption Is More Efficient Than Conventional Plasma Exchange to Remove Circulating Anti-HLA Antibodies , 2015, Blood Purification.

[22]  V. Rao,et al.  Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  C. Hunter,et al.  IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.

[24]  R. Shemin,et al.  Characterization of ventricular assist device-mediated sensitization in the bridge-to-heart-transplantation patient. , 2015, The Journal of thoracic and cardiovascular surgery.

[25]  M. Cascalho,et al.  Efficacy of plasmapheresis on donor‐specific antibody reduction by HLA specificity in post–kidney transplant recipients , 2015, Transfusion.

[26]  G. Klintmalm,et al.  Impact of IgG3 Subclass and C1q‐Fixing Donor‐Specific HLA Alloantibodies on Rejection and Survival in Liver Transplantation , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  G. Baron,et al.  Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. , 2015, Annals of the rheumatic diseases.

[28]  M. Haas,et al.  A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients , 2015, Transplantation.

[29]  R. Alloway,et al.  Prospective Iterative Trial of Proteasome Inhibitor‐Based Desensitization , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  R. Montgomery,et al.  Differential Effect of Bortezomib on HLA Class I and Class II Antibody , 2014, Transplantation.

[31]  S. Schaub,et al.  Determinants of C1q Binding in the Single Antigen Bead Assay , 2014, Transplantation.

[32]  M. Haas,et al.  Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients , 2014, Transplantation.

[33]  V. Thohan,et al.  Practical value of identifying antibodies to cryptic HLA epitopes in cardiac transplantation. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[34]  C. Ensor,et al.  Carfilzomib for Refractory Antibody Mediated Rejection and Allosensitization in Heart Transplantation , 2014 .

[35]  J. Pascual,et al.  Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? , 2013, Transplant immunology.

[36]  N. Smedira,et al.  HLA and MICA allosensitization patterns among patients supported by ventricular assist devices. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[37]  X. Jouven,et al.  Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.

[38]  M. Clatworthy,et al.  Elevated Pretransplantation Soluble BAFF Is Associated With an Increased Risk of Acute Antibody-Mediated Rejection , 2013, Transplantation.

[39]  W. Kremers,et al.  LVAD Implant as a Bridge to Heart Transplantation Is Associated with Allosensitization as Measured by Single Antigen Bead Assay , 2013, Transplantation.

[40]  F. Fallani,et al.  Occurrence of Fatal and Nonfatal Adverse Outcomes after Heart Transplantation in Patients with Pretransplant Noncytotoxic HLA Antibodies , 2013, Journal of transplantation.

[41]  M. Neurath,et al.  How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy , 2013, Nature Medicine.

[42]  Mark E. Williams,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue , 2013, Journal of clinical apheresis.

[43]  C. Haisch,et al.  The Role of Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney Transplantation Outcomes , 2013, Transplantation.

[44]  D. Monos,et al.  Persistence of anti-human leukocyte antibodies in congenital heart disease late after surgery using allografts and whole blood. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[45]  R. Rodeheffer,et al.  Donor-Specific Antibodies to Class II Antigens Are Associated With Accelerated Cardiac Allograft Vasculopathy: A Three-Dimensional Volumetric Intravascular Ultrasound Study , 2013, Transplantation.

[46]  A. Webster,et al.  Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation , 2013, Transplantation.

[47]  J. Pirk,et al.  Alloimmunosensitization in left ventricular assist device recipients and impact on posttransplantation outcome. , 2012, ASAIO journal.

[48]  A. Minguela,et al.  C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG. , 2012, Transplantation proceedings.

[49]  G. Klintmalm,et al.  Donor‐specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with Chronic rejection and graft loss after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[50]  D. Barz,et al.  Plasma Exchange and Immunoadsorption of Patients with Thoracic Organ Transplantation , 2012, Transfusion Medicine and Hemotherapy.

[51]  J. Kobashigawa,et al.  The use of the calculated panel-reactive antibody and virtual crossmatch in heart transplantation , 2012, Current opinion in organ transplantation.

[52]  S. Jordan,et al.  Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. , 2012, Discovery medicine.

[53]  N. Banner,et al.  Late Antibody-Mediated Rejection After Heart Transplantation Following the Development of De Novo Donor-Specific Human Leukocyte Antigen Antibody , 2012, Transplantation.

[54]  J. Pober,et al.  Neutralizing IL-6 Reduces Human Arterial Allograft Rejection by Allowing Emergence of CD161+ CD4+ Regulatory T Cells , 2011, The Journal of Immunology.

[55]  E. Reed,et al.  Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[56]  M. Stegall,et al.  Terminal Complement Inhibition Decreases Antibody‐Mediated Rejection in Sensitized Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[57]  S. Russell,et al.  Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. , 2011, The Journal of thoracic and cardiovascular surgery.

[58]  V. Valentine,et al.  Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. , 2011, The Annals of thoracic surgery.

[59]  D. Tyan,et al.  Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. , 2011, Human immunology.

[60]  A. Ender,et al.  HLA Antibody Specification Using Single-Antigen Beads—A Technical Solution for the Prozone Effect , 2011, Transplantation.

[61]  C. Marboe,et al.  HLA antibodies in pediatric heart transplantation , 2011, Pediatric transplantation.

[62]  L. Kucirka,et al.  Desensitization in HLA-incompatible kidney recipients and survival. , 2011, The New England journal of medicine.

[63]  X. Jouven,et al.  Very Late Heart Transplant Rejection Is Associated with Microvascular Injury, Complement Deposition and Progression to Cardiac Allograft Vasculopathy , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[64]  J. Cecka,et al.  Calculated PRA: Initial Results Show Benefits for Sensitized Patients and a Reduction in Positive Crossmatches , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[65]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[66]  N. Banner,et al.  De Novo Donor HLA‐Specific Antibodies after Heart Transplantation Are an Independent Predictor of Poor Patient Survival , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[67]  G. Berry,et al.  Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[68]  Ronny Gustafsson,et al.  Desensitization and Heart Transplantation of a Patient With High Levels of Donor-Reactive Anti-Human Leukocyte Antigen Antibodies , 2010, Transplantation.

[69]  G. Gupta,et al.  Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation , 2010, Drug design, development and therapy.

[70]  R. Starling,et al.  Management of the sensitized adult heart transplant candidate , 2010, Clinical transplantation.

[71]  A. Amodeo,et al.  Pneumatic pulsatile ventricular assist device as a bridge to heart transplantation in pediatric patients. , 2010, Artificial organs.

[72]  A. Rahmel,et al.  The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric heart transplantation report--2010. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[73]  W. Dreyer,et al.  Impact of antibodies against human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing database. , 2010, The Journal of thoracic and cardiovascular surgery.

[74]  Clive Lewis,et al.  The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[75]  S. Webber,et al.  Immunosuppression Therapy for Pediatric Heart Transplantation , 2010, Current treatment options in cardiovascular medicine.

[76]  A. Amodeo,et al.  Mechanical assist device as a bridge to heart transplantation in children less than 10 kilograms. , 2010, The Annals of thoracic surgery.

[77]  S. Jordan,et al.  Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation , 2010, Transplantation.

[78]  N. Pallet,et al.  Bortezomib as the Sole Post‐Renal Transplantation Desensitization Agent Does Not Decrease Donor‐Specific Anti‐HLA Antibodies , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[79]  E. Reed,et al.  307: The Effectiveness of a Standardized Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies (cPRA) in Sensitized Heart Transplant Candidates: Does It Make Sense To Desensitize? , 2010 .

[80]  W. Hop,et al.  Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain‐Barré syndrome , 2009, Annals of neurology.

[81]  Maryl R. Johnson,et al.  Management of allosensitized cardiac transplant candidates. , 2009, Transplantation reviews.

[82]  D. Mancini,et al.  Alloantibodies in heart transplantation. , 2009, Human immunology.

[83]  J. Platt,et al.  The role of antibodies in transplantation. , 2009, Transplantation reviews.

[84]  M. Daha,et al.  Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. , 2009, Kidney international.

[85]  J. Bradley,et al.  Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. , 2009, Human immunology.

[86]  B. Horne,et al.  Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[87]  M. Rose,et al.  Clinical relevance of complement-fixing antibodies in cardiac transplantation. , 2009, Human immunology.

[88]  Junchao Cai,et al.  Intact HLA Not &bgr;2m-free Heavy Chain-Specific HLA Class I Antibodies Are Predictive of Graft Failure , 2009, Transplantation.

[89]  Kirk R. Kanter,et al.  The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. , 2009, Journal of the American College of Cardiology.

[90]  P. Terasaki,et al.  Abrogation of Anti-HLA Antibodies via Proteasome Inhibition , 2009, Transplantation.

[91]  R. Holdsworth,et al.  Review article: Luminex technology for HLA antibody detection in organ transplantation , 2009, Nephrology.

[92]  E. Reed,et al.  Report from a consensus conference on the sensitized patient awaiting heart transplantation. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[93]  Jie Zheng,et al.  Decline in rejection in the first year after pediatric cardiac transplantation: a multi-institutional study. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[94]  R. Gajarski,et al.  HLA sensitization in pediatric pre-transplant cardiac patients supported by mechanical assist devices: the utility of Luminex. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[95]  R. Alloway,et al.  Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection , 2008, Transplantation.

[96]  M. Stegall,et al.  Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[97]  J. Friedewald,et al.  Tailoring Antibody Testing and How to Use it in the Calculated Panel Reactive Antibody Era: The Northwestern University Experience , 2008, Transplantation.

[98]  C. Canter,et al.  Biventricular Assist Devices as a Bridge to Heart Transplantation in Small Children , 2008, Circulation.

[99]  Susan Martin,et al.  Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. , 2008, Transplantation.

[100]  S. Jordan,et al.  Rituximab and intravenous immune globulin for desensitization during renal transplantation. , 2008, The New England journal of medicine.

[101]  M. Oz,et al.  Association of device surface and biomaterials with immunologic sensitization after mechanical support. , 2008, The Journal of thoracic and cardiovascular surgery.

[102]  J. Friedewald,et al.  Successful bridge to transplant in a highly sensitized patient with a complicated pump pocket infection. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[103]  S. Vaidya Clinical Importance of Anti-Human Leukocyte Antigen-Specific Antibody Concentration in Performing Calculated Panel Reactive Antibody and Virtual Crossmatches , 2008, Transplantation.

[104]  N. Banner,et al.  C4d Fixing, Luminex Binding Antibodies—A New Tool for Prediction of Graft Failure After Heart Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[105]  S. Russell,et al.  Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. , 2007, The Annals of thoracic surgery.

[106]  M. Hibi,et al.  The molecular biology of interleukin 6 and its receptor. , 2007, Ciba Foundation symposium.

[107]  S. Boslaugh,et al.  Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[108]  S. Webber,et al.  Survival in allosensitized children after listing for cardiac transplantation. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[109]  B. Meiser,et al.  Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[110]  P. Terasaki,et al.  The Importance of Anti‐HLA‐Specific Antibody Strength in Monitoring Kidney Transplant Patients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[111]  J. Kirklin,et al.  Cardiac re-transplantation in pediatrics: a multi-institutional study. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[112]  S. Chu,et al.  Effect of plasmapheresis for acute humoral rejection after heart transplantation. , 2006, Transplantation proceedings.

[113]  J. Wald,et al.  Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin , 2006, Clinical transplantation.

[114]  A. Keren,et al.  Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab. , 2006, Transplantation proceedings.

[115]  M. Fishbein,et al.  Acute antibody-mediated rejection of cardiac transplants. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[116]  A. Castro‐Beiras,et al.  Humoral Heart Rejection (Severe Allograft Dysfunction with no Signs of Cellular Rejection or Ischemia): Incidence, Management, and the Value of C4d for Diagnosis , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[117]  S. Mital,et al.  Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[118]  R. Graff,et al.  Use of rituximab to decrease panel-reactive antibodies. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[119]  J. Fallon,et al.  Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. , 2004, Transplantation proceedings.

[120]  D. Stablein,et al.  Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. , 2004, Journal of the American Society of Nephrology : JASN.

[121]  J. Jacobs,et al.  Pediatric cardiac transplantation in children with high panel reactive antibody. , 2004, The Annals of thoracic surgery.

[122]  P. Nickerson,et al.  National Conference to Assess Antibody‐Mediated Rejection in Solid Organ Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[123]  G. Opelz,et al.  SKEWING OF PRETRANSPLANT ANTI-HLA CLASS I ANTIBODIES OF IMMUNOGLOBULIN G ISOTYPE SOLELY TOWARD IMMUNOGLOBULIN G1 SUBCLASS IS ASSOCIATED WITH POORER RENAL ALLOGRAFT SURVIVAL , 2004, Transplantation.

[124]  N. Reinsmoen,et al.  Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. , 2004, Transplant immunology.

[125]  C. Hillyer,et al.  Unappreciated risk factors for transplant patients: HLA antibodies in blood components. , 2004, Human immunology.

[126]  N. Fineberg,et al.  Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1 , 2004, Transplantation.

[127]  J. Patel,et al.  The highly sensitized patient awaiting heart transplantation: success with combination therapy of plasmapheresis and intravenous gamma globulin , 2004 .

[128]  Mitchell R. Smith Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[129]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[130]  H. Eisen,et al.  Cardiac transplantation across a positive prospective lymphocyte cross‐match in sensitized recipients , 2003, Clinical transplantation.

[131]  C. Cunningham-Rundles,et al.  Utility of Intravenous Immune Globulin in Kidney Transplantation: Efficacy, Safety, and Cost Implications , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[132]  M. Mehra,et al.  Allosensitization in heart transplantation: implications and management strategies , 2003, Current opinion in cardiology.

[133]  R. Duquesnoy,et al.  Multilaboratory evaluation of serum analysis for HLA antibody and crossmatch reactivity by lymphocytotoxicity methods. , 2003, Archives of pathology & laboratory medicine.

[134]  P. Terasaki,et al.  Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities , 2003, Transplantation.

[135]  M. Dalakas Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies , 2002, Neurology.

[136]  M. Welters,et al.  A broad and strong humoral immune response to donor HLA after implantation of cryopreserved human heart valve allografts. , 2002, Human immunology.

[137]  K. Groshart,et al.  Treatment of humoral rejection with rituximab. , 2002, The Annals of thoracic surgery.

[138]  H. Hashimoto,et al.  Plasma adsorption in critical care. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[139]  J. Aranda,et al.  Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. , 2002, Transplantation.

[140]  E. Gelfand Antibody-directed therapy: past, present, and future. , 2001, The Journal of allergy and clinical immunology.

[141]  D. Mancini,et al.  Increased Prevalence of Autoimmune Phenomena and Greater Risk for Alloreactivity in Female Heart Transplant Recipients , 2001, Circulation.

[142]  S. Kaveri,et al.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.

[143]  A. Zachary,et al.  Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance. , 2001, Human immunology.

[144]  R. Hetzer,et al.  Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[145]  S. Takemoto,et al.  Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. , 2000, Transplantation.

[146]  H. Hagberg,et al.  Risk factors for side effects during first infusion of rituximab—definition of a low risk group , 2000, Medical oncology.

[147]  R. Bray,et al.  Sensitization and sensitivity: defining the unsensitized patient. , 2000, Transplantation.

[148]  L. Lambert,et al.  Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. , 2000, The Journal of thoracic and cardiovascular surgery.

[149]  P. Terasaki,et al.  Flow cytometric detection of HLA antibodies using a spectrum of microbeads. , 1999, Human immunology.

[150]  M. Oz,et al.  Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. , 1999, Circulation.

[151]  O. Press,et al.  Clinical applications of anti-CD20 antibodies. , 1999, The Journal of laboratory and clinical medicine.

[152]  J. A. Robinson,et al.  Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[153]  M. Oz,et al.  Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. , 1998, Circulation.

[154]  N. Smedira,et al.  Vascular rejection post heart transplantation is associated with positive flow cytometric cross-matching. , 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[155]  D. Reichenbach,et al.  The clinical significance of flow cytometry crossmatching in heart transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[156]  R. Dowling,et al.  Use of intravenous immunoglobulin in sensitized LVAD recipients. , 1998, Transplantation proceedings.

[157]  E. Reed,et al.  Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. , 1997, Journal of immunology.

[158]  N G Smedira,et al.  Factors influencing HLA sensitization in implantable LVAD recipients. , 1997, The Annals of thoracic surgery.

[159]  J. Kobashigawa,et al.  Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? , 1996, Circulation.

[160]  L. Lambert,et al.  Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. , 1996, Circulation.

[161]  E. Reed,et al.  Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. , 1996, Transplantation.

[162]  G. Couper,et al.  Role of panel-reactive antibody cross-reactivity in predicting survival after orthotopic heart transplantation. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[163]  D. Renlund,et al.  OUTCOME OF CARDIAC TRANSPLANT RECIPIENTS WITH A POSITIVE DONOR‐SPECIFIC CROSSMATCH—PRELIMINARY RESULTS WITH PLASMAPHERESIS , 1992, Transplantation.

[164]  J. Dwyer Manipulating the immune system with immune globulin. , 1992, The New England journal of medicine.

[165]  B. Griffith,et al.  Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[166]  C. Marboe,et al.  The role of anti-HLA antibodies in heart transplantation. , 1991, Transplantation.

[167]  J. Himmelfarb,et al.  Extracorporeal removal of anti-HLA antibodies in transplant candidates. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[168]  P. Terasaki,et al.  Significance of the positive crossmatch test in kidney transplantation. , 1969, The New England journal of medicine.

[169]  T. Edgington,et al.  HUMAN BLOOD LYMPHOCTYE CYTOTOXICITY REACTIONS WITH ALLOGENIC ANTISERA * , 1964, Annals of the New York Academy of Sciences.

[170]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.

[171]  X. Jouven,et al.  IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. , 2016, Journal of the American Society of Nephrology : JASN.

[172]  E. Reed,et al.  Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. , 2013, Methods in molecular biology.

[173]  J. Lunz,et al.  Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[174]  R. Bray Lymphocyte crossmatching by flow cytometry. , 2013, Methods in molecular biology.

[175]  R. Bray,et al.  Clinical cytometry and progress in HLA antibody detection. , 2011, Methods in cell biology.

[176]  E. Reed,et al.  The long‐term outcome of treated sensitized patients who undergo heart transplantation , 2011, Clinical transplantation.

[177]  D. Mancini,et al.  Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. , 2011, Human immunology.

[178]  J. Pirsch,et al.  Antibody-mediated rejection: treatment alternatives and outcomes. , 2009, Transplantation reviews.

[179]  R. Alloway,et al.  Proteasome inhibition reduces donor-specific antibody levels. , 2009, Transplantation proceedings.

[180]  M. Fishbein,et al.  Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[181]  A. Davis Structure and function of C1 inhibitor. , 1989, Behring Institute Mitteilungen.

[182]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.